MX9709163A - El uso de un compuesto potenciador de dopamina/reductor de prolactina para preparar composiciones para prevenir la estenosis asociada con intervencion despues de intervenciones invasivas sin derivacion. - Google Patents

El uso de un compuesto potenciador de dopamina/reductor de prolactina para preparar composiciones para prevenir la estenosis asociada con intervencion despues de intervenciones invasivas sin derivacion.

Info

Publication number
MX9709163A
MX9709163A MX9709163A MX9709163A MX9709163A MX 9709163 A MX9709163 A MX 9709163A MX 9709163 A MX9709163 A MX 9709163A MX 9709163 A MX9709163 A MX 9709163A MX 9709163 A MX9709163 A MX 9709163A
Authority
MX
Mexico
Prior art keywords
bypass
following non
invasive interventions
stenosis following
intervention
Prior art date
Application number
MX9709163A
Other languages
English (en)
Other versions
MXPA97009163A (es
Inventor
Anthony H Cincotta
Original Assignee
Ergo Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ergo Science Inc filed Critical Ergo Science Inc
Publication of MX9709163A publication Critical patent/MX9709163A/es
Publication of MXPA97009163A publication Critical patent/MXPA97009163A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Endoscopes (AREA)

Abstract

La presente invencion se refiere al uso de un compuesto potenciador de dopamina/reductor de prolactina para preparar composiciones para prevenir la estenosis después de una intervencion invasiva sin derivacion; la invencion se refiere al uso de dicho compuesto para disminuir los dolores de pecho sintomáticos despues de una intervencion invasiva sin derivacion; el uso de las composiciones comprende administrar una cantidad diaria de las mismas, de modo de proveer el compuesto potenciador de dopamina/reductor de prolactina en un tiempo predeterminado, y continuar la administracion duratne un período por lo menos suficiente como para permitir que sane la lesion vascular.
MXPA/A/1997/009163A 1995-05-31 1997-11-26 El uso de un compuesto potenciador de dopamina/reductor de prolactina para preparar composiciones para prevenir la estenosis asociada con intervencion despues de intervenciones invasivas sin derivacion MXPA97009163A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08455354 1995-05-31
US08/455,354 US5565454A (en) 1995-05-31 1995-05-31 Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions
PCT/US1996/010443 WO1996038148A1 (en) 1995-05-31 1996-05-30 Method for preventing intervention-associated stenosis following non-bypass, invasive interventions

Publications (2)

Publication Number Publication Date
MX9709163A true MX9709163A (es) 1998-03-31
MXPA97009163A MXPA97009163A (es) 1998-10-15

Family

ID=

Also Published As

Publication number Publication date
DK0828492T3 (da) 2006-03-06
EP1661571A3 (en) 2006-08-02
JP4480799B2 (ja) 2010-06-16
JP2007182447A (ja) 2007-07-19
EP0828492A4 (en) 1999-07-07
WO1996038148A1 (en) 1996-12-05
EP1661571A2 (en) 2006-05-31
EP0828492B1 (en) 2006-01-18
DE69635754T2 (de) 2006-07-27
CA2219452A1 (en) 1996-12-05
DE69635754T9 (de) 2007-03-08
US5902811A (en) 1999-05-11
JPH11507334A (ja) 1999-06-29
ATE315936T1 (de) 2006-02-15
ES2255080T3 (es) 2006-06-16
DE69635754D1 (de) 2006-04-06
US5565454A (en) 1996-10-15
EP0828492A1 (en) 1998-03-18

Similar Documents

Publication Publication Date Title
HU9402771D0 (en) Pharmaceutical compositions for wound healing and treatment of fibrotic disorders
BG97678A (en) Beta -carotene and/or vitamin e therapy for inhibition of major vascular events
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
HU9203632D0 (en) Method for utilization of diphenyl-butyl-piperazine-carboxamides in treatment of diseases of material-dependency
WO2002058684A3 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
EP1661571A3 (en) Medicaments for preventing intervention-associated stenosis following non-bypass, invasive interventions
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
CA2204277A1 (en) Combined meningitis vaccine
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
CA2294921A1 (en) Levobupivacaine and its use
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
GB9103764D0 (en) Compositions
EP0429522A4 (en) Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
EP0744176A3 (en) Methods for inhibiting bone loss
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
ATE237349T1 (en) Fat-binding polymers
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
Kapfhammer et al. Cimoxatone and Moclobemide, Two New MAO-lnhibitors, in the Treatment of Major Depressive Disorder
IE782550L (en) Cis-(3,3,5) - trimethylcyclohexanol
UA10302A (uk) Спосіб лікуваhhя чоловічого гіпогоhадизму
UA10754A (uk) Спосіб лікуваhhя артеріальhих гіпертеhзій різhого геhезу
UA10249A (uk) Спосіб лікування діабетичних ангіопатій